Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000-cr nutraceuticals category
Mamaearth-parent Honasa Consumer is acquiring 58% of Gurugram-based Fluence Pharma at a ₹135 crore enterprise value, with the remaining 42% over 5-7 years. The deal launches new subsidiary Honasa Health, marking entry into India's ₹16,000-crore nutraceuticals market growing at 11%.
What happened
Honasa Consumer acquires 58% of nutraceuticals firm Fluence Pharma at ₹135 crore EV, with remaining 42% over 5-7 years, marking Mamaearth-parent's entry into
Key facts
- 58% stake
- ₹135 crore EV
- 42% in 5-7 years
- share ₹420
- nutraceuticals market ₹16,000 crore
- 11% growth
- FY26 net profit ₹200 crore
- revenue ₹2,391 crore
- 3,000 dermatologists
Why this matters
Staggered majority deals like this — control now, balance over 5-7 years tied to performance — are the cleanest template for category-entry M&A in adjacent consumer health verticals.